PHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.
|
|
- Stella Moore
- 5 years ago
- Views:
Transcription
1 PHA 58 ase Study 4 (Answers) Spring 4. PT is a patient stabilized on chronic phenytoin therapy. She has just been diagnosed with rheumatoid arthritis and her physician would like to start her on high dose aspirin therapy. However, the physician is concerned about a possible drug interaction with aspirin. You find in your pocket reference that high dose aspirin is known to displace phenytoin from its plasma protein binding sites. Describe (as you would to the physician) the clinical relevance of this interaction and your therapeutic recommendations. While it is true that aspirin displaces phenytoin from its plasma protein binding sites, there is no reason to alter the phenytoin dose or switch from aspirin to another agent just because of the drug interaction. Specifically, phenytoin is a low extraction, restrictively cleared drug. This means that it s clearance is determined by unbound clearance and fraction unbound. Addition of aspirin to the regimen will lead to an increased unbound fraction of phenytoin. This will increase phenytoin s clearance and decrease it s total drug concentration. HOWEER, unbound concentration will be unchanged as it is determined only by dose and unbound clearance. Therefore the free (and pharmacologically active) phenytoin concentration will be unchanged in spite of this drug interaction, thus changes in dosage will be unnecessary. However, it is important for the physician to understand that the total phenytoin concentration will decrease, in spite of no change in the free concentration. For example, if phenytoin free fraction increases from % to 5%, the following total concentration will change as follows: Total p Unbound p/fu. Remember unbound p doesn t change in this interaction because unbound clearance doesn t change. Here is an example of what can be observed: Before aspirin: total p - mcg/ml fu -. unbound p -. mcg/ml After aspirin: total p - 8 mcg/ml fu -.5 unbound p -. mcg/ml If the medical team is unaware of this, and measures a total phenytoin level, the normal reaction would be to increase the dose, which would be inappropriate and likely to lead to toxicity.
2 . A phenytoin patient has a plasma concentration of mg/l at 3mg/day and 5mg/L at 4mg/day. Using graph paper, determine the Km and as well as the dose needed to produce a concetration of 5mg/L Dose needed to produce a concentration of 5mg/L 35mg/day
3 3. E. A., (37y, 7 kg, male), had been taking 3mg/day of phenytoin; however, his dose was increased to 35 mg/day because his reported plasma concentration was only 8 mg/l. Now his reported plasma phenytoin concentration is mg/l. Both of the reported plasma concentrations represent steady-state level. alculate a new daily dose of phenytoin that will result in a steady state level of 5 mg/l (Salt factor.9). K m R R when salt factor is considered, it can be rewritten as: K m R R S S Now, we have levels of phenytoin () resulting from different daily doses (R ), so we can set up equations with unknown parameters (Km and ), and caculate K m and by solving the equations, which turn out to be: K m ( D ( D ( D ( D D ( S ( D ) D D D S ( D * daily dose, D R ) In this case, (3.9) (35.9) ( 8) ( 8) 36.5( mg / day) (3.9) 8 (35.9) ( ) K m.5( mg / L) 3.9 Then, the new daily dose will be:
4 m R 337.5( mg / ) ( K + ) S (.5 + 5).9 day m
5 4..S., a 36-year-old, 7-kg woman, is to be given carbamazepine as an anticonvulsant agent. alculate a daily dose that will produce an average steadystate plasma concentration of 6 mg/l. Maintenance dose (L)(ssave)( τ ) ( S )( F ) (.64L / kg / hr 7kg )(6mg / ()(.8 ) L )(4hr / day) 86.4mg / day Start on the initial daily dose of to 4 mg, with increase of about mg every 7 to 4 days till it reaches 8 mf daily.
6 5. O.S., a 48-year-old, 59 kg male patient, received a living-related renal transplant ½ years ago. He is currently receiving cyclosporine 3 mg orally as the solution BID and, in addition, prednisone 3 mg/day and azathioprine 75 mg/day. O.S. s current serum creatinine is. mg/dl and his steady-state cyclosporine trough concentration is 59 µg/l. The physician has ruled out the possibility of rejection and feels that the recent rise in serum creatinine is due to cyclosporine toxicity. What questions would one ask O.S. and how would one adjust his cyclopsporine regimen in order to achieve a new steady-state cyclosporine concentration of approximately µg/l? - confirm that O.S. has been taking his cyclosporine 3 mg BID as prescribed and determine if any new medications have been added to his regimen - verify that the time of sampling relative to when he took his last dose to ensure that the level is in fact a trough and not a peak concentration - if there are no obvious reasons for the elevated cyclosporine level, at least one cyclosporine dose should be held and then O.S. should be restarted on a new regimen - to calculate the new dose: Dosedesired cpssdesired cpsscurrent Dosecurrent µg 59µg / / L L 3mg.7mg mg
PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5128 Final Exam Spring 2004 Version A On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name There are 18 questions. Total /120 pts Final 2004 1 1. T.P., a 66-year-old,
More informationPHA 5128 Spring 2000 Final Exam
PHA 128 Spring 2000 Final Exam On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name TYPED KEY Questions Points 1. /1 2. /1 3. /1 4. /1. /10 6. /10. /10 8. /10
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationName: UFID: PHA Exam 2. Spring 2013
PHA 5128 Exam 2 Spring 2013 1 Carbamazepine (5 points) 2 Theophylline (10 points) 3 Gentamicin (10 points) 4 Drug-drug interaction (5 points) 5 Lidocaine (5 points) 6 Cyclosporine (5 points) 7 Phenobarbital
More informationThus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.
PHA 5128 Dose Optimization II, Spring 2012, Case Study V Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationCarbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8
PHA 5128 Dose Optimization II, Spring 2013, Case Study IV Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationPHA 5128 Spring 2009 First Exam (Version B)
Name: UFID: PHA 5128 Spring 2009 First Exam (Version B) On my honor, I have neither given nor received unauthorized aid in doing this assignment. Print: Sign: Version B Q1: Phenytoin (10) Q2: procainamide
More informationPHA Case Studies V (Answers)
PHA 5128 Case Studies V (Answers) 1. A 100 kg patient is to be treated p.o. with sodium phenytoin capsules. Assuming a phenytoin volume of distribution of 0.7 L/kg, Km of 4 mg/l and Vmax of 7 mg/kg/day,
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationTDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:
Lecture 9: Very important supplements TDM Effect of hepatic disease on drugs monitoring: Generally, hepatic clearance is determined by three main factors: - Liver blood flow (LBF). - Intrinsic capacity
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationAdjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook
More informationCLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE
CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE Joseph K. Ritter, Ph.D. Assoc. Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@vcu.edu This self study module will reinforce the
More informationpharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.
Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration
More informationPHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set
More informationTDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages
TDM Lecture 8 5 th Stage TDM of Digoxin Use of Digoxin Serum Concentrations to Alter Dosages Linear Pharmacokinetics Method This method is used in steady-state condition. We compute the new dose of digoxin
More informationPHA5128 Dose Optimization II Case Study 3 Spring 2013
Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What
More information. Although there is a little
PHA 58 Spring 007 Case study 4. Baby girl A, 3kg, 5 days, is receiving phenobarbital because of neonatal seizures. An IV loading dose of phenobarbital sodium of 0mg/kg was given followed by maintenance
More informationLD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)
PHARMKIN WORKSHOP A PHARMACOKINETICS TEACHING SIMULATION Joseph K. Ritter, Ph.D. Associate Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@mail2.vcu.edu Tompkins-McCaw Libray Room 2-006
More informationPHA Final Exam Fall 2006
PHA 5127 Final Exam Fall 2006 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPHARMACOKINETICS SMALL GROUP II:
PHARMACOKINETICS SMALL GROUP II: Question 1 Why are some drug therapies initiated with a loading dose? Emphasize that LD establishes initial therapeutic level quickly. The time to reach the steady-state
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationMyrna Y. Munar, Pharm.D., BCPS
Phenytoin PK Myrna Y. Munar, Pharm.D., BCPS Associate Professor Clickers Turn clicker on by pressing down menu button Enter you OSU student ID number The up/down diagonal arrows button on the left is the
More informationTDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.
TDM Lecture 7 5 th Stage TDM of Digoxin Digoxin uses and elimination Uses: Digoxin is usually used in heart failure associated and atrial fibrillation. Elimination: About 75% of digoxin clearance occurred
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007
PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007 1. L.J., a 30 year old male, was diagnosed congestive heart failure (CHF). He is 5'9" tall and weights 80 kg. He was given Furosemide
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationBassett Healthcare Clinical Laboratory
Therapeutic Drug Level Collection Guidelines Anti-epileptic drugs (carbamazepine, phenobarbital, phenytoin, primidone, valproic acid) Consider collecting after steady state conditions are reached, i.e.
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationUSES OF PHARMACOKINETICS
CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program Office of Clinical Research Training and Medical Education National Institutes of Health Clinical Center
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationPHENYTOIN DOSING INFORMATION. Adult Dosage
PHENYTOIN DRUGDEX Evaluations DOSING INFORMATION Adult Dosage Normal Dosage Important Note ) Due to the risk of severe hypotension and cardiac arrhythmias, the rate of IV phenytoin administration should
More information4WS Neurology. Table of Contents
4WS Neurology Table of Contents 1. Phenytoin Preparations... Page 2 Monitoring... Page 2 Therapeutic Range... Page 2 Loading Doses... Page 2 Maintenance Doses... Page 3 Sampling Times... Page 3 Dose Adjustment...
More informationPHA Final Exam Fall 2001
PHA 5127 Final Exam Fall 2001 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /12 pts 2. /8 pts 3. /12 pts 4. /20 pts 5. /27 pts 6. /15
More informationA Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients
CMU. J. Nat. Sci. (2012) Vol. 11(1) 77 A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients Yupaporn Preechagoon 1 and Peeraya Somsaard 2* 1 Department
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /150 pts 1 Question Set I (True or
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationPHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4120 Second Exam Key Fall 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /10 ponts 2. /20 points 3. /10 points 4. /10 points
More informationPharmacokinetic parameters: Halflife
Pharmacokinetic parameters: Halflife (t 1/2 ) 1. By definition t 1/2 is the time required for the concentration to fall by one half. For drugs with first order kinetics this is a constant. 2. Half-life
More informationPHA First Exam Fall 2003
PHA 5127 First Exam Fall 2003 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /14 pts 2. /6 pts 3. /15 pts 4. /12 pts 5. /20 pts 6. /10pts
More informationClinical Pharmacokinetics. Therapeutic Drug Monitoring of Phenytoin
Clinical Pharmacokinetics Therapeutic Drug Monitoring of Phenytoin Dr. Maysa Suyagh School of Pharmacy University of Jordan Phenytoin primarily used as an anticonvulsant and has been used in the treatment
More informationDoses Target Concentration Intervention
1 Doses Target Concentration Intervention 2 Problem 1 Questions 1-2 Susan is a 28 year old woman who has had epilepsy since she was 5 years old. She has been on, and off, anticonvulsant medication since
More informationOutline. How should we do TDM? Does the evidence support TDM outcomes
Overcoming Barriers to TDM: Information and the TDM Renaissance How to integrate PK intelligence with routine clinical data Alexander A. Vinks, PharmD, PhD, FCP Professor, Director Pediatric Pharmacology
More informationMetabolism. Objectives. Metabolism. 26 July Chapter 28 1
Metabolism bjectives Describe various processes by which drugs are metabolized Describe induction and inhibition of metabolism Use the venous equilibration model to describe hepatic clearance and the effect
More informationPHARMACOKINETICS SMALL GROUP I:
PHARMACOKINETICS SMALL GROUP I: Question 1 Absorption of the anti-fungal agent, itraconazole, is dependent on a low gastric ph. Calculate the relative concentrations of a weak acid (with a pka of 5.4)
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationBasics of TDM with example drugs
Basics of TDM with example drugs Pharmacokinetic differences in drug handling between patients produce wide variability in serum drug concentrations, but dosage adjustments are generally only required
More informationLippincott Questions Pharmacology
Lippincott Questions Pharmacology Edition Two: Chapter One: 1.Which one of the following statements is CORRECT? A. Weak bases are absorbed efficiently across the epithelial cells of the stomach. B. Coadministration
More informationMultiple IV Bolus Dose Administration
PHARMACOKINETICS Multiple IV Bolus Dose Administration ١ Multiple IV Bolus Dose Administration Objectives: 1) To understand drug accumulation after repeated dose administration 2) To recognize and use
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationNew drugs necessity for therapeutic drug monitoring
New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range
More informationThe importance of clearance
The importance of clearance The calculation of clearance can be especially useful in optimizing dosing of patients The clearance includes both the volume of distribution and the elimination rate The clearance
More informationChapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University
Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University Estimating renal function An accurate estimation of renal
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationPolicy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
More informationIV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro
IV Vancomycin dosing and Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary Medicine Unique
More information6 semanas de embarazo. Topamax effect potassium level. Inicio / Embarazo / 6 semanas de embarazo
Inicio / Embarazo / 6 semanas de embarazo 6 semanas de embarazo Topamax effect potassium level Dec 16, 2009. Since the effects of topiramate on acid-base balance and potassium levels have not been well
More informationValproate Case 3: Formulations Jose de Leon, MD
Valproate Case 3: Formulations 2-12-16 Jose de Leon, MD 3.Valproate Case 3 Described in J Clin Psychiatry 2004;65:724-5 http://www.ncbi.nlm.nih.gov/pubmed/15163266 Pharmacological explanation provided
More informationINTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS
Title of guideline (must include the word Guideline (not protocol, policy, procedure etc) INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Author: Contact Name and Job Title
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationThe Japanese Pharmacokinetic (PK) Study of Sirolimus-Coated Bx VELOCITY Balloon-Expandable Stent in Patients With de novo Coronary Artery Lesions
The Japanese Pharmacokinetic (PK) Study of Sirolimus-Coated Bx VELOCITY Balloon-Expandable Stent in Patients With de novo Coronary Artery Lesions - The Japan PK Study - Masato Nakamura Department of Cardiovascular
More informationTEACHERS TOPICS Role of Protein Binding in Pharmacokinetics
TEACHERS TOPICS Role of Protein Binding in Pharmacokinetics Reza Mehvar, PhD School of Pharmacy, Texas Tech University Health Sciences Center Submitted January 3, 2005; accepted February 13, 2005; published
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationThe Benefits of Leflunomide
Page 1 of 5 Angell Navigation Site Navigation Emergency The Benefits of Leflunomide By Doug Brum, DVM www.angell.org/internalmedicine internalmedicine@angell.org 617-541-5186 Leflunomide is a newer immunosuppressant
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More informationM O N T H E R A P E D R O R I N G. Dr Tom Hartley UTAS HLS 2014
T H E R A P E U T I C D R U G M O N I T O R I N G Dr Tom Hartley UTAS HLS 2014 TOPICS 1) Why we do TDM 2) What drugs do we monitor 3) How our data assists Clinical Pharmacists & Doctors 4) Bioavailability
More informationCase Study 2 Answers Spring 2006
Case Study 2 Answers Spring 2006 1. The volume of distribution of diazepam in a group of normal subjects (60 kg, ideal body weight) was found to be 105 L. In another group of patients (110 kg), the volume
More informationSurgery in the renal transplant patient
Surgery in the renal transplant patient Prevalence of renal transplants in Australia Prevalence according to State/Territory Overall patient and graft survival following renal transplantation: short term
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationClinical Policy: Baricitinib (Olumiant) Reference Number: CP.PHAR.135 Effective Date: Last Review Date: 11.18
Clinical Policy: (Olumiant) Reference Number: CP.PHAR.135 Effective Date: 07.24.18 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationPrednisone tapering schedule 60 mg
Buscar... Prednisone tapering schedule 60 mg I ve taken 60 mg. of prednisone for 5 days, no taper, as instructed by ER for breathing problems caused by interstitial pneumonitus. Absolutely no problems.
More informationANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO
ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept
More informationDefining refractory epilepsy
Defining refractory epilepsy Pasiri S, PMK Hospital @ 8.30 9.00, 23/7/2015 Nomenclature Drug resistant epilepsy Medically refractory epilepsy Medical intractable epilepsy Pharmacoresistant epilepsy 1 Definition
More informationClinical Policy: Sarilumab (Kevzara) Reference Number: CP.PHAR.346 Effective Date: Last Review Date: 11.18
Clinical Policy: (Kevzara) Reference Number: CP.PHAR.346 Effective Date: 07.18.17 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationANSWER # 1 PHARMACOLOGY. Methadone answers Stoltzfus 4/5/2012 METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017
METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017 Ky Stoltzfus, MD Assistant Professor, Internal Medicine University of Kansas Medical Center ANSWER # 1 Your response might be
More informationPrinciples of Medication Use in Older Adults ANNE L. HUME, PHARMD PROFESSOR OF PHARMACY UNIVERSITY OF RHODE ISLAND
Principles of Medication Use in Older Adults ANNE L. HUME, PHARMD PROFESSOR OF PHARMACY UNIVERSITY OF RHODE ISLAND Financial Disclosure None of the planners, speakers, and/or members of the CME committee
More informationUSES OF PHARMACOKINETICS
LINIAL PHARMAOKINETIS Juan J.L. Lertora, M.D., Ph.D. Director linical Pharmacology Program Office of linical Research Training and Medical Education National Institutes of Health linical enter September
More informationPrednisone 50 mg for 5 days for asthma
Prednisone 50 mg for 5 days for asthma Search free delivery prednisone 50 mg for 5 days asthma. 2018 is 9 Best Erection Pills That Work! 100% prednisone 50 mg for 5 days asthma,online. Up to 20% Off prednisone
More informationAminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive
Aminoglycosides Uses: Treatment of serious gram-negative systemic infections and some grampositive infections such as infective endocarditis. Disadvantage: aminoglycosides are their association with nephrotoxicity
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:
Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other SOFOSBUVIR/VELPATASVIR EPCLUSA TBD CUSTOMER SERVICE REPRESENTATIVE (CSR) If the member lives in Rhode Island or if the prescribing physician
More informationC OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:
LESSON 2 Basic Pharmacokinetics C OBJECTIVES After completing Lesson 2, you should be able to: 1. Define the concept of apparent volume of distribution and use an appropriate mathematical equation to calculate
More informationPHAR 7632 Chapter 16
PHAR 7632 Chapter 16 Routes of Excretion Routes of Excretion Student Objectives for this Chapter After completing the material in this chapter each student should:- be able to describe the various routes
More informationIntrinsic + Common = aptt. Extrinsic + Common = PT. Common Pathway
Anticoagulant Cases 12 11 Intrinsic + Common = aptt 9 8 10 7 4 Extrinsic + Common = PT 5 2 Common Pathway 1 Xa Inhibitors rivaroxaban (Xarelto) apixaban (Eliquis) edoxaban (Savaysa) What is true regarding
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationTarget Concentration Intervention
1 Target Concentration Intervention Dose Individualization using Monitoring of Patient Response Nick Holford University of Auckland 2 Objectives 1) Appreciate how a target concentration (TC) strategy is
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationClinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date:
Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important
More information